Licensor Terminates Key Onvansertib Agreement; Cardiff Oncology Vows to Fight
CRDF sits 26% above its 52-week low of $1.48.
Summary
Cardiff Oncology's licensor, Nerviano Medical Sciences, has terminated the license agreement for onvansertib, the company's lead drug, escalating a critical legal dispute.
Key Events · Legal and Risk Events · CRDF
-
Licensor Terminates Agreement
Nerviano Medical Sciences (NMS) has formally terminated the License Agreement for onvansertib, Cardiff Oncology's lead drug, citing alleged material breaches.
-
Cardiff Oncology Disputes Termination
Cardiff Oncology promptly responded to NMS, stating the termination notice is 'legally ineffective, factually unsupported and procedurally improper,' and will continue to perform under the agreement.
-
Escalation of Critical Dispute
This action significantly escalates the legal dispute previously disclosed on May 19, 2026, where Cardiff Oncology filed a lawsuit against NMS.
-
Impact on Lead Drug
The termination directly threatens the future of onvansertib, a drug for which the FDA recently agreed on a Phase 3 trial design, and is critical for the company already facing a 'going concern' warning.
Analysis · CRDF · Life Sciences
Nerviano Medical Sciences (NMS) has formally terminated its license agreement with Cardiff Oncology for onvansertib, the company's lead drug. This is a significant escalation of the previously disclosed legal dispute over patent inventorship and development efforts. The termination notice from NMS, which Cardiff Oncology is disputing as 'legally ineffective,' poses an existential threat to the company's pipeline, especially given its recent 'going concern' warning. The future of onvansertib, for which the FDA recently agreed on a Phase 3 trial design, is now highly uncertain.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $129.9M. The 52-week trading range was $1.48 to $4.56. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.